drugset / Trial / NCT00543634
Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women
Phase 1
Completed
30 enrolled
Wyeth is now a wholly owned subsidiary of Pfizer
MDS Pharma Services · collab
RandomizedCrossoverOpen-labelHealth-services research
Summary
The purpose of the study is to evaluate the safety and efficacy of new tablet formulations of Premarin®/medroxyprogesterone (MPA).
Timeline
- Start
- 2007-10
- Primary completion
- 2007-12
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | conjugated estrogens | Other / unclassified | 0.625 mg | — |
| Comparator | medroxyprogesterone acetate | Other / unclassified | 2.5 mg | — |
| Comparator | medroxyprogesterone acetate | Other / unclassified | 5 mg | — |
| Comparator | medroxyprogesterone acetate | Other / unclassified | 10 mg | — |
Indications
No indication recorded.